
Dentsply Sirona Appoints John Fortson as Chief Financial Officer
Track XRAY's AI-powered predictions, market trends, and investment insights.
You don't hold XRAY in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedNegative EPS and a negative P/E ratio indicate that Dentsply is currently unprofitable, which is a clear red flag for equity holders. Without evidence of a near‑term inflection in earnings, the risk/reward skews to the downside despite any potential for operational turnaround.
The stock trades at $10.09, modestly up 0.2% over the last month but still meaningfully below its 200‑day moving average of $12.00, indicating a sustained downtrend. Trading below the 200‑day average typically reflects weak medium‑term momentum and a lack of strong buying interest.
Alternative data are mixed: web traffic is sizable, and LinkedIn and Instagram followings are growing modestly, while Twitter/X and Facebook followers are slightly declining. Job openings are down 7.5% month over month, which could indicate either efficiency efforts or a cautious hiring stance amid operational or demand uncertainty.
Overall, the combination of negative earnings, a stock price trading below its 200‑day moving average, and only modestly constructive alternative data supports a bearish stance on Dentsply at this time. Until profitability improves and the share price can sustainably recover above key technical levels, the risk profile remains elevated.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Dentsply Sirona (XRAY) is currently trading at $10.00 on the NASDAQ, with a modest intraday gain of +1.2% on volume of over 3.4 million shares. The stock carries a market capitalization of approximately $2.0 billion, a significant compression from prior valuation levels that reflects ongoing headwinds in the professional dental market. As a manufacturer of dental equipment, CAD/CAM technologies, and consumables across two core segments, XRAY operates in a specialized but competitive medical instruments space where demand cycles and dental practice economics play a decisive role in revenue trajectory.
TrendEdge's AI model assigns XRAY a score of 4 out of 10, signaling a below-average near-term outlook. This score reflects a confluence of weak quantitative signals: the stock is trading at depressed price levels relative to its market cap history, with no strong momentum catalyst visible in the current data window. The AI score aggregates price action, volume dynamics, and alternative data inputs — and with 499 active job postings suggesting some operational continuity, the score does not indicate imminent collapse but does flag a lack of compelling upside conviction. A score of 4/10 typically warrants caution for new long positions.
Key catalysts to monitor for XRAY in 2026 include any recovery in dental procedure volumes, progress with its SureSmile clear aligner platform, and execution on cost restructuring. The 499 active job postings indicate the company is maintaining workforce investment, which could signal operational stabilization. However, risks remain elevated: margin pressure in the consumables segment, competitive threats in dental CAD/CAM, and a sub-$11 share price leave limited technical buffer. Any guidance revision or segment-level deterioration could pressure the stock further.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
471,765
Twitter Followers
11,973
Instagram Followers
34,695
LinkedIn Followers
395,348
Job Postings
472
LinkedIn Employees
11,270
News Mentions
0
Key Metrics